The group is asking the DEA not to impede "the legitimate practice of medicine," but the agency says it is not a barrier to care.

By Andis Robeznieks, AMNews staff. Feb. 21, 2005.

A new voice has joined the chorus claiming that recent actions by the U.S. Drug Enforcement Administration appear to impede the prescribing of controlled substances to treat pain.

The National Assn. of Attorneys General, in a Jan. 19 letter, called on DEA Administrator Karen P. Tandy to meet with representatives of the organization to "find ways to prevent abuse and diversion without infringing on the legitimate practice of medicine or exerting a chilling effect on the willingness of physicians to treat patients who are in pain."
The letter was signed by the attorneys general from 29 states and the District of Columbia. The effort was led by Oklahoma Attorney General and NAAG Past President W.A. Drew Edmondson, who said he was approaching the issue from a consumer-protection standpoint.

"If our consumers are not receiving what they need and want as health care consumers, then that's a problem for the attorney general," Edmondson said. "The new position of the DEA has at least the potential -- if not the actual effect -- of being a barrier to doctors prescribing the proper drugs for treating pain. I fully support efforts to combat diversion, but we have to find ways to combat diversion that does not impact on good patient care."

Edmondson said it appears that investigating physicians might be the new focus of DEA anti-diversion efforts, and he disagrees with that approach. "We should concentrate on drugs that are illegally on the streets and work backward from that to find out how they got illegally on the streets," he said. "It should not be the other way around looking at doctors."

In August 2004, after working for more than two years with experts in the field of pain medicine, the DEA released a frequently-asked-questions document on prescribing controlled substances for pain treatment that sought to balance physician concerns about effective treatment and law enforcement issues regarding diversion of prescription drugs. The DEA removed the document from its Web site in October 2004, and posted a notice in the Nov. 16 Federal Register stating that the document contained incorrect information. Some physicians said the new policy statement appeared to criminalize more prescribing activity.
Most Americans say they would prefer to die at home, free of pain and without unwanted medical intervention.

On Jan. 18, another notice was posted notifying the public that the agency was in the process of preparing another document and was seeking comments from physicians and other interested parties about what they wanted the document to include.

The NAAG letter expressed surprise that the DEA "apparently shifted its policy" from balancing medical and law enforcement concerns.

"We are concerned that state and federal policies are diverging with respect to the relative emphasis on ensuring the availability of prescription pain medications to those who need them," the letter stated.

DEA spokesman Rusty Payne denied there had been a shift in policy.

"DEA has not changed any policy related to this issue," Payne said in an e-mail. "The reason for taking down the FAQs was simply because there was some information that was incorrect. ... DEA has not changed its enforcement emphasis with respect to investigating physicians involved in the illegal prescribing of pharmaceutical narcotics."

He added that no meeting had been scheduled with the NAAG.
Most Americans die in a hospital or nursing home.

Attorney and pain medicine advocate Mary Baluss, the director of the Pain Law Initiative in Washington, D.C., said she cheered when she first saw the NAAG letter, but then her enthusiasm was dampened somewhat when she saw that attorneys general for 21 states had not signed the letter.

Edmondson, however, was satisfied with the signatures the letter received. "Getting all 50 to sign is pretty near impossible -- getting three attorneys in a room to agree on something is problematic," he said.

Edmondson's interest in pain treatment stems from his work promoting better end-of-life care.

He said that interest was sparked when he attended a bioethics program where he learned that most Americans would prefer to die at home with friends and family, free of pain and without unwanted medical intervention. Instead, he said, most Americans die in pain at a hospital or nursing home.

"I was thinking, 'What's wrong with this picture and what can I do about it?' " Edmonson said.

He formed an end-of-life care task force in Oklahoma and, while serving as the 2002-03 NAAG president, selected end-of-life care as the subject of his presidential initiative.

"There has been an increased focus, I believe, by medical licensing boards on the undertreatment of pain and, with the shift by the DEA, doctors are in a tough, tough position," Edmondson said. "Anything we can do to lessen that squeeze, I believe, is helpful, and that's the purpose of the letter to the DEA."

American Medical Association policy states that "physicians who appropriately prescribe and/or administer controlled substances to relieve intractable pain should not be subject to the burdens of excessive regulatory scrutiny, inappropriate disciplinary action or criminal prosecution."




By Andis Robeznieks, AMNews staff. Feb. 7, 2005.

The U.S. Drug Enforcement Administration is preparing a document that will address its role as defined by the Controlled Substances Act. The DEA has invited physicians and others to submit comments on what they would like the document to address.

According to the announcement, published in the Jan. 18 Federal Register, those interested have until March 21 to submit comments.
The announcement was the latest in a series of notices about a frequently-asked-questions document on prescribing controlled substances for pain treatment that was posted on the DEA Web site in August 2004 and then withdrawn in October.

The document took more than two years to finish and was co-authored by the DEA, the University of Wisconsin Pain & Policy Studies Group and the Last Acts Partnership, with Russell K. Portenoy, MD, serving as the panel's lead expert on pain treatment.

Dr. Portenoy, chair of the Dept. of Pain Medicine and Palliative Care at New York's Beth Israel Medical Center and faculty member for the AMA online series on pain treatment, said he had little enthusiasm for going through the process again.

But PPSG Director David Joranson said it appeared that there were new people at the DEA working on prescription drug diversion, and they need to be educated on the issues. "I think everyone in the pain field -- clinicians, administrators and patients -- should take the DEA request very seriously," he said.

Joranson said the FAQ document was valuable in that it educated clinicians on law enforcement's drug diversion concerns, and it informed law enforcement about medical issues.

The president-elect of the American Academy of Pain Medicine, Scott Fishman, MD, said he would mention this in a letter to the DEA. "It will reiterate the position of balance, assert that aggressive pain medicine is possible without perpetuating addiction, and caution regulators about policies that try to solve the problem of drug diversion by restricting access to pain medicine of those who legitimately need them," he said.

The DEA said it had no comment.



Since Feb. 27, 2005 Your are visitor Hit Counter to this page